Apollomics Inc Cl A (APLM)

$6.20 -0.13 (-2.05%)
Market Cap 6.67M
Revenue (ttm) 1.49M
Net Income (ttm) -53.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,614.77%
Debt to Equity Ratio 0.00
Volume 2,597
Avg Vol 33,098
Day's Range N/A - N/A
Shares Out 1.10M
Stochastic %K 100%
Beta 0.92
Analysts Strong Buy
Price Target $6.50

Company Profile

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multip...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 209 4055
Fax: 650 288 1674
Address:
989 East Hillsdale Blvd., Suite 220, Foster City, United States
ShadowPathfinder
ShadowPathfinder Aug. 23 at 5:47 AM
$APLM Apollomics Inc is an oncology company with clinical stage assets and partnership dependencies
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 14 at 3:44 PM
$APLM update pending
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 5 at 9:41 AM
$CDT $APLM need u both soon
0 · Reply
exconsocancelme
exconsocancelme Jul. 30 at 1:50 PM
$APLM can I get this again @ $5.70 for a 3rd swing probably not.
0 · Reply
BaxterLove
BaxterLove Jul. 30 at 1:39 AM
$SCPXD look at @Maazo and how successful hes been! well done sir! this douche nozzle pumped SCPX from about 5.00 down to its .01. same with $HOLO and now…his latest con is $APLM if youre in that stock, get ready for about a 80-90%+ haircut that he will claim hes buying en masse while encouraging all to buy into or HOLD and mocking anyone that contradicts. con artist do what con artists do
0 · Reply
houstonexpat
houstonexpat Jul. 28 at 1:19 PM
$APLM Don't forget the warrants APLMW
0 · Reply
houstonexpat
houstonexpat Jul. 28 at 1:19 PM
$APLM Great close on Friday, seems to be continuing today
0 · Reply
VolcanicTrades
VolcanicTrades Jul. 25 at 3:09 PM
$GLMD the folks than $APLM should take a look here. We liked $PBM did we not?
0 · Reply
smsy83
smsy83 Jul. 25 at 2:14 PM
$APLM any news coming up?
0 · Reply
_KiLLa_
_KiLLa_ Jul. 24 at 7:55 PM
$APLM ty for that closing action
0 · Reply
Latest News on APLM
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Apr 3, 2025, 4:05 PM EDT - 5 months ago

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

Mar 31, 2025, 8:00 AM EDT - 5 months ago

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Dec 20, 2024, 8:00 AM EST - 8 months ago

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Dec 10, 2024, 4:05 PM EST - 9 months ago

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Aug 14, 2024, 6:00 AM EDT - 1 year ago

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Jul 16, 2024, 4:47 PM EDT - 1 year ago

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Jul 3, 2024, 8:00 AM EDT - 1 year ago

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apr 25, 2024, 8:30 AM EDT - 1 year ago

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apr 10, 2024, 7:00 AM EDT - 1 year ago

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 3:57 PM EDT - 1 year ago

Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Mar 4, 2024, 7:00 AM EST - 1 year ago

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 7:00 AM EST - 1 year ago

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Jan 19, 2024, 4:15 PM EST - 1 year ago

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference

Jan 17, 2024, 4:30 PM EST - 1 year ago

Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Jan 3, 2024, 7:00 AM EST - 1 year ago

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Apollomics to Present at the 2024 Biotech Showcase

Jan 2, 2024, 4:30 PM EST - 1 year ago

Apollomics to Present at the 2024 Biotech Showcase

Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Nov 29, 2023, 7:30 AM EST - 1 year ago

Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)

Nov 28, 2023, 7:00 AM EST - 1 year ago

Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)

Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

Nov 16, 2023, 8:30 AM EST - 1 year ago

Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

Oct 31, 2023, 8:30 AM EDT - 1 year ago

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

Oct 26, 2023, 8:50 AM EDT - 1 year ago

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

Oct 23, 2023, 8:30 AM EDT - 2 years ago

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

Oct 16, 2023, 6:55 PM EDT - 2 years ago

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Sep 28, 2023, 4:17 PM EDT - 2 years ago

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline

Aug 29, 2023, 6:21 AM EDT - 2 years ago

Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline

Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)

Apr 26, 2023, 7:45 AM EDT - 2 years ago

Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)

ANGO

Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R.

Apr 11, 2023, 8:30 AM EDT - 2 years ago

Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R.

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Jan 13, 2023, 4:13 PM EST - 2 years ago

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

Oct 7, 2022, 4:05 PM EDT - 3 years ago

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

ShadowPathfinder
ShadowPathfinder Aug. 23 at 5:47 AM
$APLM Apollomics Inc is an oncology company with clinical stage assets and partnership dependencies
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 14 at 3:44 PM
$APLM update pending
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 5 at 9:41 AM
$CDT $APLM need u both soon
0 · Reply
exconsocancelme
exconsocancelme Jul. 30 at 1:50 PM
$APLM can I get this again @ $5.70 for a 3rd swing probably not.
0 · Reply
BaxterLove
BaxterLove Jul. 30 at 1:39 AM
$SCPXD look at @Maazo and how successful hes been! well done sir! this douche nozzle pumped SCPX from about 5.00 down to its .01. same with $HOLO and now…his latest con is $APLM if youre in that stock, get ready for about a 80-90%+ haircut that he will claim hes buying en masse while encouraging all to buy into or HOLD and mocking anyone that contradicts. con artist do what con artists do
0 · Reply
houstonexpat
houstonexpat Jul. 28 at 1:19 PM
$APLM Don't forget the warrants APLMW
0 · Reply
houstonexpat
houstonexpat Jul. 28 at 1:19 PM
$APLM Great close on Friday, seems to be continuing today
0 · Reply
VolcanicTrades
VolcanicTrades Jul. 25 at 3:09 PM
$GLMD the folks than $APLM should take a look here. We liked $PBM did we not?
0 · Reply
smsy83
smsy83 Jul. 25 at 2:14 PM
$APLM any news coming up?
0 · Reply
_KiLLa_
_KiLLa_ Jul. 24 at 7:55 PM
$APLM ty for that closing action
0 · Reply
exconsocancelme
exconsocancelme Jul. 24 at 7:49 PM
$APLM out $5.60 killin it!
0 · Reply
exconsocancelme
exconsocancelme Jul. 24 at 5:54 PM
$APLM nice dip buy
0 · Reply
_KiLLa_
_KiLLa_ Jul. 24 at 3:49 PM
$APLM thanks for the dip now. back above 5 for the flip. Dragging that av does suck but it pays off for sure.
0 · Reply
VolcanicTrades
VolcanicTrades Jul. 24 at 11:37 AM
$PBM did the folks that ran $APLM add? Low float with results catalyst. Your type of play since you tag me all the time in your things (not shade) Move $16-$25 in chart 🔥📈
1 · Reply
smsy83
smsy83 Jul. 23 at 4:24 PM
$APLM what’s wrong with this stock?
0 · Reply
MyPreciousShares
MyPreciousShares Jul. 23 at 1:48 PM
$APLM might be a good entry point here soon
0 · Reply
EyeYamStewPeed
EyeYamStewPeed Jul. 23 at 1:39 PM
$APLM Down it goes🤣
0 · Reply
LQQKER_INSIDER
LQQKER_INSIDER Jul. 23 at 10:38 AM
$APLM Pumpers, how am my doing so far? 💋
0 · Reply
cmartin0528
cmartin0528 Jul. 23 at 2:07 AM
$APLM this POS better do something or I am out STAT!
0 · Reply
_KiLLa_
_KiLLa_ Jul. 22 at 9:17 PM
$APLM give me a good day this week.. and not drop on buying atm please. Tf was that
1 · Reply
Jusbemoney
Jusbemoney Jul. 22 at 8:05 PM
$APLM
0 · Reply
houstonexpat
houstonexpat Jul. 22 at 7:43 PM
$APLM Large warrant order gone through APLMW over 27K
0 · Reply